Certara, Inc.

Listed Company

CERTCIK 0001827090NasdaqLarge AcceleratedServices-Prepackaged SoftwareDelawareFY ends Dec 31

Period

FY 2025

Revenue

$418.84M

Net Income

$-1.59M

Total Assets

$1.56B

Equity

$1.06B

Shares Out

159.14M

Op. Cash Flow

$96.33M

Business

Certara, Inc. provides biosimulation technology and solutions enabling Model-Informed Drug Development (MIDD) for the global biopharmaceutical industry. It offers software and technology-enabled services, including mechanistic and empirical biosimulation platforms (e.g., Simcyp Simulator, Phoenix PK/PD suite), regulatory science tools (CoAuthor, GlobalSubmit), data automation (Pinnacle 21, D360), and cheminformatics from Chemaxon. Key business areas include biosimulation solutions, scientific informatics and data pipelines, regulatory science, and technology-enabled services such as QSP and pharmacometrics. Certara serves life sciences companies, contract research organizations, regulators, and academic institutions worldwide through licensed software, cloud-hosted platforms, and professional services.

Summary from filing dated 2025-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	419	385	354	336	286
Cost of revenues	161	155	141	133	—
Sales and marketing	54	47	32	27	20
Research and development	41	37	34	28	20
General and administrative	85	94	95	72	80
Depreciation and amortization	57	54	46	2	2
Goodwill impairment expense	0	0	47	0	0
Total operating expenses	237	232	254	171	161
Income (loss) from operations	21	−2	−41	33	14
Interest expense	−20	−22	−23	−18	—
Net other income	6	6	9	−14	−17
Total other expenses	−13	−15	−14	—	—
Income (loss) before income taxes	8	−17	−55	19	−3
Provision (benefit) for income taxes	9	−5	214,000	4	10
Net loss	−2	−12	−55	15	−13
Foreign currency translation adjustment, net of tax of $6, $(956), $(717)	19	−3	3	−10	−5
Change in fair value of interest rate swap, net of tax of $253, $$(827), $1,393	−3	−3	−2	6	—
Total other comprehensive income (loss)	15	−6	637,000	−4	−2
Comprehensive income (loss)	14	−18	−55	10	−16
Basic (in dollars per share)	−0.01	−0.08	−0.35	0.09	−0.09
Diluted (in dollars per share)	−0.01	−0.08	−0.35	0.09	−0.09
Basic (in shares)	160	160	159	157	150
Diluted (in shares)	160	160	159	159	150

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	189	179	235	237	186
Accounts receivable, net of allowances for credit losses of $2,235 and $2,164, respectively	104	102	85	83	70
Prepaid expenses and other current assets	22	29	20	20	19
Total current assets	315	311	340	342	275
Property and equipment, net	2	2	3	2	3
Operating lease right-of-use assets	12	14	10	14	13
Goodwill	773	757	716	718	703
Intangible assets, net of accumulated amortization of $415,804 and $338,809, respectively	447	485	487	487	512
Deferred income taxes	5	4	4	4	4
Other long-term assets	2	2	3	6	2
Total assets	1,557	1,575	1,563	1,573	1,512
Accounts payable	3	4	5	8	7
Accrued expenses	67	56	57	35	30
Current portion of deferred revenue	75	78	61	52	45
Current portion of long-term debt	3	3	3	3	3
Other current liabilities	4	5	4	5	1
Total current liabilities	153	146	130	103	92
Deferred revenue, net of current portion	2	1	1	3	2
Deferred income taxes	34	40	51	65	76
Operating lease liabilities, net of current portion	8	11	7	10	8
Long-term debt, net of current portion and debt discount	290	292	288	290	292
Other long-term liabilities	5	25	39	22	25,000
Total liabilities	494	516	516	493	470
Commitments and contingencies	—	—	—	—	—
Preferred shares, $0.01 par value, 50,000,000 and no shares authorized, issued, and outstanding as of December 31, 2025 and 2024, respectively	0	0	0	—	—
Common shares, $0.01 par value, 600,000,000 shares authorized, 164,005,450 and 161,958,810 shares issued as of December 31, 2025 and 2024, respectively; 159,139,562 and 161,009,112 shares outstanding as of December 31, 2025 and 2024, respectively	2	2	2	2	—
Additional paid-in capital	1,256	1,217	1,178	1,150	1,120
Accumulated deficit	−130	−128	−116	−61	−76
Accumulated other comprehensive income(loss)	2	−13	−8	−8	−4
Treasury stock at cost, 4,865,888 and 949,698 shares at December 31, 2025 and 2024, respectively	−67	−18	−9	−3	−38,000
Total stockholders' equity	1,063	1,059	1,047	1,080	1,042
Total liabilities and stockholders' equity	1,557	1,575	1,563	1,573	1,512

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	75	68	56	2	2
Amortization of debt issuance costs	568,000	1	2	2	2
Provision for credit losses	1	1	684,000	1	130,000
Equity-based compensation expense	33	35	28	30	29
Change in fair value of contingent considerations	−4	8	24	0	0
Total deferred	−8	−13	−17	−12	−1
Accounts receivable	428,000	−16	152,000	−15	−10
Prepaid and other assets	−902,000	−3	711,000	126,000	585,000
Accounts payable and accrued expenses, and other liabilities	4	−5	−6	9	1
Deferred revenue	−3	14	28,000	10	5
Other operating activities, net	−1	—	—	—	—
Other operating activities, net	—	2	2	169,000	—
Net cash provided by operating activities	96	80	83	93	60
Capital expenditures	−2	−2	−2	−1	−1
Capitalized software development costs	−25	−19	−13	−11	−8
Investment in intangible assets	0	0	−54,000	0	0
Business acquisitions, net of cash acquired	0	−91	−64	−15	−261
Net cash used in investing activities	−27	−112	−80	−28	−270
Common stock repurchase program	−43	0	0	—	—
Proceeds from borrowings on term loan debt	0	6	0	0	—
Payment of debt issuance costs	0	−1	0	0	−3
Payments on long-term debt obligations	−3	−2	−3	−3	—
Payments for business acquisition related contingent consideration	−13	−15	0	0	—
Payment of taxes on shares and units withheld for employee taxes	−5	−9	−6	−3	−272,000
Net cash used in financing activities	−64	−21	−9	−7	123
Effect of foreign exchange rate changes on cash and cash equivalents	4	−3	2	−4	−524,000
Net increase (decrease) in cash, cash equivalents	10	−56	−5	53	−87
Cash paid for interest	19	23	19	17	14
Cash paid for taxes	12	15	19	10	9
Contingent liabilities established in connection with business acquisition	0	0	11	20	0
Stock issuance or establish liabilities related to business acquisition contingent consideration	6	4	0	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro